Premium
Transplantation of allogeneic peripheral blood stem cells after myeloablative treatment of a patient in blastic crisis of chronic myelocytic leukemia
Author(s) -
Sasaki Atsuko,
Tsukaguchi Machiko,
Hirai Manabu,
Ohira Hidehiro,
Nakao Yoshitaka,
Yamane Takahisa,
Park Keunsik,
Im Taesung,
Tatsumi Noriyuki
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830470110
Subject(s) - medicine , busulfan , stem cell , cyclophosphamide , bone marrow , leukemia , apheresis , transplantation , haematopoiesis , granulocyte colony stimulating factor , immunology , prednisolone , hematopoietic stem cell transplantation , chemotherapy , biology , platelet , genetics
A 48‐year‐old man in blastic crisis of chronic myelocytic leukemia received a transplant of allogeneic peripheral blood stem cells. The donor was his HLA‐identical sister, who refused to donate bone marrow cells, but agreed to donate peripheral blood stem cells. The patient received standard transplant conditioning with cyclophosphamide (120 mg/ kg) and busulfan (16 mg/kg). Peripheral blood stem cells were mobilized with granulocyte colony stimulating factor and collected by apheresis. After transplantation, the white blood cell count and the result of microscopic analysis of the bone marrow became normal, and the leukocyte karyotype became 46XX. DNA fingerprinting showed complete chimerism. Graft‐versus‐host disease was suppressed with cyclosporine and methyl‐prednisolone. The patient died of recurrence of leukemia on day 102+. © 1994 Wiley‐Liss, Inc.